A Multicenter Retrospective Noninterventional Follow-up Study in Patients with Sickle Cell Pain Crisis Who Previously Participated in the Sustain Trial in the United States Successor Study

Nirmish Shah(Duke University), Abdullah Kutlar(Augusta University), Jincy Paulose, Dram Laine, Savita Nandal(Berkeley College), Ralph V. Boccia(Center for Cancer and Blood Disorders), Brandon M. Hardesty(Indiana Hemophilia and Thrombosis Center), Das Purkayastha, Walter K. Kraft(Thomas Jefferson University)

Blood

November 29, 2018

10.1182/blood-2018-99-111332

Cited by 2

Related Papers

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

|Breast Cancer Research and Treatment|2017|761

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial

|The Lancet|2015|518

Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia

|New England Journal of Medicine|2010|425

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

|The Lancet Oncology|2013|387

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2019|386